Honz Pharmaceutical Co Ltd

Honz Pharmaceutical Co Ltd has a market capitalization of 3.27 billion CNY and a price-to-book ratio of 3.64, indicating that the market values the company at a premium to its book value. The company's liquidity position is assessed as medium, with a current ratio of 0.52, suggesting that it may struggle to meet short-term obligations with its current assets. Free cash flow is negative at -275.59 million CNY, and capital expenditures are -92.12 million CNY, indicating that the company is investing in its operations but is not generating sufficient cash to cover these expenses. Profitability metrics show that the company is currently unprofitable, with a net income of -230.14 million CNY and an operating income of -257.32 million CNY. Return on equity is -25.58%, and return on assets is -12.85%, both significantly below the industry median for pharmaceutical companies. The company's gross profit of 244.89 million CNY is also below the industry average, indicating that it is not capturing as much margin as its peers. The company's revenue is concentrated in a single geographic market, with no disclosed international operations, which increases its exposure to local economic and regulatory risks. There is no information available on revenue by business segment, but the company's primary activity is in pharmaceuticals, which is a capital-intensive and highly competitive industry. Looking ahead, the company's revenue outlook is uncertain, with no clear direction provided in the available data. The company's operating cash flow of 121.24 million CNY is positive, but it is not sufficient to cover the negative free cash flow, indicating that the company may need to rely on external financing to fund its operations. The company's debt-to-equity ratio of 0.63 suggests that it is not overly leveraged, but the negative net cash position after subtracting total debt is a concern. Recent filings and transcripts do not provide any new insights into the company's strategic direction or operational performance. The company's risk assessment indicates a low probability of dilution, but the medium liquidity risk and negative net income suggest that the company may face challenges in maintaining its current operations without additional capital.